Some retrospective analyses suggest that NSCLC tumours with EGFR mutation or anaplastic lymphoma kinase (ALK) rearrangements (EGFR+/ALK+) do not respond well to these treatments when compared with EGFR−/ALK− tumours, indicating that EGFR mutant patients are not ideal candidates for anti-PD-1/PD-L1 therapies, compared to patients with KRAS mutation or wild-type EGFR [13–16]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.